99 High Street, 30th Floor

Boston, MA 02110


March 8, 2024


Via EDGAR Transmission


Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549


Attention: Jessica Dickerson


Re: Praxis Precision Medicines, Inc.

Registration Statement on Form S-3

Filed March 5, 2024

File No. 333-277656


To the addressee set forth above:


Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Praxis Precision Medicines, Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-277656, the “Registration Statement”) be accelerated by the Securities and Exchange Commission to 4:00 p.m., Eastern Time, on March 12, 2024, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Jennifer A. Yoon at (617) 880-4540.


If you have any questions regarding the foregoing, please do not hesitate to contact Jennifer A. Yoon of Latham & Watkins LLP at (617) 880-4540. Thank you in advance for your consideration.



Very truly yours,


  Praxis Precision Medicines, Inc.
  By:   /s/ Marcio Souza
    Name: Marcio Souza
    Title: Chief Executive Officer



 Alex Nemiroff, Praxis Precision Medicines, Inc.

Jennifer A. Yoon, Latham & Watkins LLP